伤寒疫苗市场：依疫苗类型、给药途径及地区划分

预计到2026年，伤寒疫苗市场规模为5.586亿美元，到2033年将达到12.44亿美元。预计从2026年到2033年，其复合年增长率将达到12.2%。

伤寒是由伤寒沙门氏菌引起的细菌感染疾病，其症状包括持续发烧、头痛、噁心、食慾不振、便秘或腹泻。细菌通常透过受污染的食物或水经口进入人体，穿透肠壁，并在淋巴组织中繁殖。随后，细菌进入血液，引起菌血症。饮用受污染的水或食用受污染的水清洗过的食物的人有感染伤寒的风险。伤寒主要发生在卫生条件不佳、缺乏干净饮用水的地区。伤寒疫苗是生物製药，可提供免疫力，保护个体免受伤寒感染。

目前，世界卫生组织（世卫组织）建议的伤寒疫苗有三种，分别是：

• 注射型伤寒结合疫苗（TCV）：该疫苗含有与破伤风类毒素蛋白结合的 Vi 多醣抗原，核准用于 6 个月及以上的儿童和 45 岁以下的成人。
• 这是一种基于纯化 Vi 抗原的非结合多醣疫苗（称为 Vi-PS 疫苗），适用于 2 岁及以上人群。
• 适用于 6 岁及以上族群的口服减毒活疫苗 Ty21a 胶囊剂。

市场动态

预计在预测期内，各国政府和其他组织加大力度提高民众对伤寒疫苗的认识，以及新疫苗的普及，将推动伤寒疫苗市场成长。例如，2019年2月，全球疫苗免疫联盟（Gavi）与世界卫生组织、美国疾病管制与预防中心以及辛巴威卫生署合作，发起了宣传活动。 Gavi是官民合作关係，致力于帮助全球一半的儿童接种疫苗，并预防一些世界上最致命的疾病。这项宣传活动的目标是在津巴布韦首都的九个郊区为32.5万人接种新型伤寒结合疫苗（TCV）。全球至少有1,240万名儿童被列为「零剂量」儿童，他们生活在缺乏基本服务（包括医疗保健）的贫困社区。

本报告的主要特点

• 本报告指出了各个细分市场的潜在商机，并概述了该市场中一系列有吸引力的投资提案。
• 此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 本节根据以下参数介绍全球伤寒疫苗市场主要企业的概况：公司概况、产品系列、主要亮点、财务绩效和策略。
• 本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
• 《全球伤寒疫苗市场》报告面向该行业的众多相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过分析全球伤寒疫苗市场中使用的各种策略矩阵来促进决策。

目录

第一章：分析目标与假设

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、监管与趋势分析

• 市场动态
  • 促进因素
  • 阻碍因素
  • 市场机会
• 影响分析
• 新产品上市及核准
• PEST分析
• 品牌知名度策略
• 救赎方案
• 供不应求
• 临床试验分析
• 蛇咬伤事件高发生的国家
• 市场准入的挑战

第四章：全球伤寒疫苗市场：依疫苗类型划分（2026-2033 年）

• 活病毒疫苗
• 荚膜多醣疫苗
• 结合疫苗
• 其他的

第五章：全球伤寒疫苗市场：依给药途径划分（2026-2033 年）

• 口服
• 注射

第六章：全球伤寒疫苗市场：依地区划分（2026-2033年）

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 亚太其他地区
• 中东
  • GCC
  • 以色列
  • 其他中东国家
• 非洲
  • 北非
  • 中非
  • 南非

第七章 竞争情势

• 热图分析
• 公司简介
  • GlaxoSmithKline Plc.
  • Sanofi SA
  • Bharat Biotech
  • Bio-Med Pvt. Ltd.
  • PT Bio Farma
  • PaxVax, Inc.
  • Shanghai Institute of Biological Products Co., Ltd.
  • Prokarium

第八章

• 参考
• 分析方法

Typhoid Fever Vaccines Market is estimated to be valued at USD 558.6 Mn in 2026 and is expected to reach USD 1,244.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 12.2% from 2026 to 2033.

Typhoid fever is a bacterial infection caused by Salmonella typhi, which causes symptoms such as prolonged fever, headache, nausea, loss of appetite, and constipation or sometimes diarrhea. The bacterium usually enters the body through the mouth by the ingestion of contaminated food or water, penetrates the intestinal wall, and multiplies in lymphoid tissue. It then enters the bloodstream and causes bacteremia. People who drink contaminated water or eat food washed in contaminated water can develop typhoid fever. Typhoid fever is majorly caused in area with poor sanitation and lack of clean drinking water. Typhoid fever vaccines are the biological formulations, which provide immunity and protect an individual against typhoid fever.

Currently there are three typhoid vaccines recommended by the World Health organization (WHO) for use which include:

• Injectable typhoid conjugate vaccine (TCV), consisting of Vi polysaccharide antigen linked to tetanus toxoid protein licensed for children from 6 months of age and adults up to 45 years of age
• Injectable unconjugated polysaccharide vaccine based on the purified Vi antigen (known as Vi-PS vaccine) for persons aged two years and above, and
• Oral live attenuated Ty21a vaccine in capsule formulation for those over six years of age

Market Dynamics

Increasing initiatives by governments and various other organizations to increase awareness about typhoid vaccine and rising access of new vaccines is expected to drive the typhoid fever vaccines market growth during forecast period. For instance, in February 2019, Gavi, the Vaccine Alliance in partnership with WHO, Center for Disease Control and Prevention and Zimbabwe's Ministry of Health launched a campaign to tackle typhoid outbreak in Zimbabwe. Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world's children against some of the world's deadliest diseases. The campaign aims to vaccinate 325,000 people in nine suburbs of Zimbabwe's capital with new typhoid conjugate vaccine (TCV). At least 12.4 million children worldwide are categorized as 'zero-dose', living in missed communities that cannot access many essential services, including health care.

Key features of the study

• This report provides an in-depth analysis of the global typhoid fever vaccines market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global typhoid fever vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global typhoid fever vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global typhoid fever vaccines market

Market Segmentation

• By Vaccine Type
  • Live Attenuated Vaccine
  • Capsular Polysaccharide Vaccines
  • Conjugate Vaccine
  • Others
• By Route of Administration
  • Oral
  • Parenteral
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Key Players
  • GlaxoSmithKline Plc.
  • Sanofi SA
  • Bharat Biotech
  • Bio-Med Pvt. Ltd.
  • PT Bio Farma
  • PaxVax, Inc.
  • Shanghai Institute of Biological Products Co., Ltd.
  • Prokarium

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Vaccine Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Novel Product Launch/Approval
• PEST Analysis
• Awareness Strategy
• Reimbursement Scenario
• Typhoid Fever Vaccines Shortage
• Clinical Trial Analysis
• Countries with High Number of Incidents of Snake Bites
• Market Entry Challenges

4. Global Typhoid Fever Vaccines Market, By Vaccine Type, 2026 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Live Attenuated Vaccine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
• Capsular Polysaccharide Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
• Conjugate Vaccine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)

5. Global Typhoid Fever Vaccines Market, By Route of Administration, 2026 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
• Parental
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)

6. Global Typhoid Fever Vaccines Market, By Region, 2026 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2026-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • GlaxoSmithKline Plc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sanofi SA
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bharat Biotech
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bio-Med Pvt. Ltd.
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • PT Bio Farma
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • PaxVax, Inc.
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Shanghai Institute of Biological Products Co., Ltd.
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Prokarium
    • Company Introduction
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

• References
• Research Methodology
• About Us and Sales Contact